Advertisement

Amino Acids

, Volume 35, Issue 1, pp 195–200 | Cite as

Characterisation of the barrier caused by luminally secreted gastro-intestinal proteolytic enzymes for two novel cystine-knot microproteins

  • M. Werle
  • H. Kolmar
  • R. Albrecht
  • A. Bernkop-Schnürch
Article

Summary.

It was the aim of this study to evaluate the stability of two novel cystine-knot microproteins (CKM) SE-ET-TP-020 and SE-MC-TR-020 with potential clinical relevance towards luminally secreted proteases of the gastrointestinal tract in order to gain information about their potential for oral administration. Therefore, the stability of the two CKM and the model-drug insulin towards collected porcine gastric and small intestinal juice as well as towards isolated proteolytic enzymes was evaluated under physiological conditions. No intact SE-ET-EP-020 was detected after few seconds of incubation with porcine small intestinal juice. SE-ET-TP-020 was also degraded in porcine gastric juice. Furthermore, SE-ET-TP-020 was extensively degraded by isolated chymotrypsin, trypsin and pepsin. Moreover, it was degraded by elastase. SE-MC-TR-020 was degraded entirely within approximately 2 h when incubated in porcine small intestinal juice, whereas no degradation was observed within a 3 h incubation period with porcine gastric juice. In presence of the isolated proteolytic enzymes, SE-MC-TR-020 was only slightly degraded by trypsin and pepsin, whereas elastase caused no degradation to SE-MC-TR-020 at all. Chymotrypsin was the protease that caused most degradation to SE-MC-TR-020. The model drug insulin was degraded extensively by chymotrypsin, elastase, pepsin and trypsin as well as by porcine gastric and porcine small intestinal juice. In conclusion, a precise characterisation of SE-ET-TP-020 and SE-MC-TR-020 degrading luminally secreted GI enzymes has been made, which is an important and substantial prerequisite for the further optimisation of these CKM.

Keywords: Cystine-knot microproteins – CKM – Oral delivery – Enzymatic degradation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Avrutina, O, Schmoldt, HU, Gabrijelcic-Geiger, D, Le Nguyen, D, Sommerhoff, CP, Diederichsen, U, Kolmar, H 2005Trypsin inhibition by macrocyclic and open-chain variants of the squash inhibitor MCoTI-IIBiol Chem38613011306PubMedCrossRefGoogle Scholar
  2. Bernkop-Schnürch, A 1998The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteinsJ Control Rel52116CrossRefGoogle Scholar
  3. Bernkop-Schnürch, A, Fragner, R 1996Investigations into the diffusion behaviour of polypeptides in native intestinal mucus with regard to their peroral administrationPharm Sci2361363Google Scholar
  4. Christmann, A, Walter, K, Wentzel, A, Kratzner, R, Kolmar, H 1999The cystine knot of a squash-type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of conformationally constrained peptidesProtein Eng12797806PubMedCrossRefGoogle Scholar
  5. Colgrave, ML, Craik, DJ 2004Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knotBiochemistry4359655975PubMedCrossRefGoogle Scholar
  6. Craik, DJ, Daly, NL, Bond, T, Waine, C 1999Plant cyclotides: a unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motifJ Mol Biol29413271336PubMedCrossRefGoogle Scholar
  7. Craik, DJ, Daly, NL, Waine, C 2001The cystine knot motif in toxins and implications for drug designToxicon394360PubMedCrossRefGoogle Scholar
  8. Craik, DJ, Cemazar, M, Daly, NL 2006The cyclotides and related macrocyclic peptides as scaffolds in drug designCurr Opin Drug Discov Devel9251260PubMedGoogle Scholar
  9. Doggrell, SA 2004Intrathecal ziconotide for refractory painExpert Opin Investig Drugs13875877PubMedCrossRefGoogle Scholar
  10. Grain, L 1973Isolation of oxytocic peptides from Oldenlandia affinis by solvent extraction of tetraphenylborate complexes and chromatography on sephadex LH-20Lloydia36207208PubMedGoogle Scholar
  11. Kratzner, R, Debreczeni, JE, Pape, T, Schneider, TR, Wentzel, A, Kolmar, H, Sheldrick, GM, Uson, I 2005Structure of Ecballium elaterium trypsin inhibitor II (EETI-II): a rigid molecular scaffoldActa Crystallogr D Biol Crystallogr6112551262PubMedCrossRefGoogle Scholar
  12. Loretz, B, Föger, FA, Werle, M, Bernkop-Schnürch, A 2006Oral gene delivery: strategies to improve stability of pDNA towards intestinal digestionJ Drug Targ14311319CrossRefGoogle Scholar
  13. Pallaghy, PK, Nielsen, KJ, Craik, DJ, Norton, RS 1994A common structural motif incorporating a cystine knot and a triple-stranded beta-sheet in toxic and inhibitory polypeptidesProtein Sci318331839PubMedCrossRefGoogle Scholar
  14. Swarbrick, J, Boylan, JC 2002Encyclopedia of pharmaceutical technology2Marcel Dekker, Inc.New York885Google Scholar
  15. Werle, M, Schmitz, T, Huang, H, Wentzel, A, Kolmar, H, Bernkop-Schnürch, A 2006aThe potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug deliveryJ Drug Targ14137146CrossRefGoogle Scholar
  16. Werle, M, Samhaber, A, Bernkop-Schnürch, A 2006bDegradation of teriparatide by gastro-intestinal proteolytic enzymesJ Drug Targ14109115CrossRefGoogle Scholar
  17. Werle, M, Bernkop-Schnürch, A 2006cStrategies to improve plasma half life time of peptide and protein drugsAmino Acids30351367CrossRefGoogle Scholar
  18. Woodley, JF 1994Enzymatic barriers for GI peptide and protein deliveryCrit Rev Ther Drug Carrier Syst116195PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • M. Werle
    • 1
  • H. Kolmar
    • 2
  • R. Albrecht
    • 1
  • A. Bernkop-Schnürch
    • 3
  1. 1.ThioMatrix GmbHResearch Center InnsbruckInnsbruckAustria
  2. 2.TU DarmstadtClemens Schöpf Institut, Fachbereich BiochemieDarmstadtGermany
  3. 3.Department of Pharmaceutical TechnologyLeopold Franzens Universität InnsbruckInnsbruckAustria

Personalised recommendations